Ratings Moves: ING,...
Health Care: Drugs
Emergent BioSolutions Incorporated (EBS: NYSE)
$14.16 -0.10 | -0.70%
05/24/13 - 04:02 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 14.16 |
| 52 Week High | 16.99 |
| 52 Week Low | 12.50 |
| Avg. Daily Vol. (Mil) | 0.24 |
| Beta (3 year) | 0.98 |
| Share Related Items | |
| Mkt Cap (Mil) | 511.48 |
| Shares Out (Mil) | 36.12 |
| Float (Mil) | 25.09 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.70 |
| Current Ratio | 5.40 |
| LT Debt/ Equity | 0.13 |
| Total Debt / Equity | 0.14 |
| Valuation Ratios | |
| Price Earnings | 22.80 |
| Price/Sales | 1.86 |
| Price/Book | 1.17 |
| Price/Cash Flow | 22.90 |
| Per Share Data | |
| Earnings | 0.62 |
| Sales | 7.60 |
| Book Value | 12.06 |
| Cash Flow | 0.62 |
| Business Summary | |
|---|---|
| Emergent BioSolutions, Inc. is a biopharmaceutical company, which is focused on the development, manufacture and commercialization of vaccine and immune-related therapeutic that assist the body's immune system to prevent or treat disease. | |
| General Information | |
| 2273 Research Boulevard
Suite 400 Rockville, MD 20850 |
|
| www.emergentbiosolutions.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 877 | |
| CEO: Daniel J. Abdun-Nabi | |
| Short Interest | |
| Current Month (Mil) | 1.26 |
| Previous Month (Mil) | 1.19 |
| Short Interest Ratio (Days) | 4.70 |
| Management Effectiveness | |
| Return on Equity | 2.10 |
| Return on Assets | 1.70 |
| Return on Investments | 1.90 |
| Profitability | |
| Gross Margin | 88.60 |
| EBIT Margin | 11.10 |
| Profit Margin | 3.40 |
Portfolios with EBS
- Portfolio NameUser Type
- UserGFNN Stockdiagnostics 12
- UserGFNN Stockdiagnostics 10
- Contributor9 Health Care Stocks With 1...
- UserRMF watchlist
- Userinvst2011
- UserDividend & Stable
- UserMSSB Trading
- UserPART 2 JPMorgan 28th Annual...
- Userdurfee
- UserBEN COLLEGE
Latest EBS Headlines from TheStreet
- Emergent BioSolutions Breaks Above 200-Day Moving Average - Bullish For EBS 04.17.13 | 04:04 pm
- TheStreet Ratings Top 10 Rating Changes 03.25.13 | 01:03 pm
- Emergent BioSolutions Incorporated Stock Downgraded (EBS) 03.21.13 | 05:03 am
- Stocks Under $10: Stealth Drug Play
08.29.12 | 06:08 am - Emergent BioSolutions' Management Presents At Wedbush 2012 Life Sciences Management Access Conference Call (Transcript) 08.14.12 | 01:08 pm
- Emergent BioSolutions' CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.02.12 | 10:08 pm
- Emergent BioSolutions' CEO Hosts Annual Shareholder Meeting Conference (Transcript) 05.17.12 | 01:05 pm
- Emergent BioSolutions Incorporated Stock Downgraded (EBS) 05.09.12 | 05:05 am
- Emergent BioSolutions CEOs Discuss 1Q 2012 Results - Earnings Call Transcript 05.04.12 | 12:05 am
- Emergent BioSolutions Incorporated Stock Upgraded (EBS) 03.15.12 | 06:03 am
Press Releases for EBS
- Emergent BioSolutions Reports Financial Results For Fourth Quarter And Full Year 2012 - Business Wire 03.07.13 | 04:03 pm
- Emergent BioSolutions To Present At Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.11.13 | 07:02 am
- Data From Historic Phase IIb Clinical Trial For Tuberculosis Vaccine Candidate MVA85A Published In The Lancet - Business Wire 02.04.13 | 07:02 am
- Emergent BioSolutions To Release Fourth Quarter And Full Year 2012 Financial Results And Conduct A Conference Call On March 7, 2013 - Business Wire 02.01.13 | 07:02 am
- Emergent BioSolutions Initiates Phase 2 Study In Pursuit Of A Post-Exposure Prophylaxis Indication For BioThrax - Business Wire 01.22.13 | 07:01 am
- Emergent BioSolutions Initiates Phase 2 Clinical Trial For Next Generation Anthrax Vaccine NuThrax - Business Wire 01.17.13 | 07:01 am
- Emergent BioSolutions Announces Preliminary 2012 Financial Results And Provides Guidance For 2013 - Business Wire 01.07.13 | 07:01 am
- Emergent’s TRU-016 For CLL Receives Orphan Medicinal Product Designation From European Commission - Business Wire 01.02.13 | 07:01 am
- Emergent BioSolutions Secures Exclusive U.S. Commercial Rights To Next Generation Pandemic Influenza Vaccine Candidate - Business Wire 12.28.12 | 12:12 pm
- Emergent BioSolutions To Present At 31st Annual J.P. Morgan Healthcare Conference - Business Wire 12.03.12 | 07:12 am
Partner Headlines for EBS
- Biodefense: Live By Government Contracts, Die By Government Contracts - Seeking Alpha 05.12.13 | 08:05 am
- Emergent BioSolutions Earnings: Here’s Why the Stock is Rising Now - Wall St. Cheat Sheet 05.02.13 | 08:05 am
- After-Hours Earnings Report for March 7, 2013 : HRB, COO, THO, P, FNSR, WX, ZQK, MAIN, EBS, SQNM, CMTL, CPK - NASDAQ 03.07.13 | 07:03 pm
- Emergent Inks Deal with VaxInnate - Analyst Blog - Zacks 12.31.12 | 03:12 pm
- Emergent Biosolutions Secures Exclusive US Commercial Rights to NextGen Pandemic Influenza Vaccine Candidate - Benzinga 12.28.12 | 12:12 pm
- Is Johnson & Johnson A Strong Buy Candidate? - Seeking Alpha 03.23.12 | 05:03 pm
- Company News for October 7, 2011 - Corporate Summary - Zacks 10.07.11 | 10:10 am
- Progress Software Reports Positive Quarter, Poor Guidance - Benzinga 09.27.11 | 04:09 pm
- Fisher Investments' Healthcare Picks: Large Caps Trumping Small Caps - Seeking Alpha 07.14.11 | 09:07 am
- Progress Software Roll Over in the After-Hours - Benzinga 06.28.11 | 04:06 pm
